Single-Center Contemporary Clinical Outcomes after Endovascular Treatment in Patients with De Novo Femoropopliteal Lesions between 2017 and 2019

Background: Drug-coated balloons (DCBs) and drugeluting stents (DES) were available for treating femoropopliteal disease since 2017 and 2019. However, there are few reports to investigate whether approval of DCB and DES improved primary patency in clinical practice. Materials and Methods: We divided consecutive 407 patients into 2017 (n= 93), 2018 (n= 128), and 2019 (n= 186) groups, undergoing endovascular therapy (EVT) for de novo femoropopliteal lesions in our hospital. We retrospectively compared clinical characteristics, procedure, and one-year patency between the three groups. Results: Baseline characteristics were not different except for the lower rate of popliteal lesions in 2017 (p= 0.030). Use of DCB increased from 7.5% in 2017 to 38.7% in 2019, and use of DES from 0.0% in 2018 to 24.2% in 2019. Oneyear primary patency increased significantly both from 2017 to 2018 (62.7% vs. 70.8%, p= 0.036) and from 2018 to 2019 (70.8% vs. 80.5%, p= 0.025). Cox proportional multivariate analysis revealed that restenosis was independently associated with advanced age (p= 0.036) and hemodialysis (p= 0.003). Conversely, use of paclitaxel-based devices (p< 0.001) and larger diameter of finalized devices (p= 0.005) were protective factors against restenosis. Conclusion: One-year primary patency after EVT in femoropopliteal lesions was improved annually by utilizing DCB and DES, individually.